Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
crossref(2023)
摘要
The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要